Regeneron Pharmaceuticals Competitors and Similar CompaniesClear all

Regeneron Pharmaceuticals's competitors and similar companies include Intersect ENT, Catalent, Bristol Myers Squibb, Idorsia, Amgen, Sanofi and Biogen.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.
Intersect ENT
Intersect ENT
Intersect ENT is an ear, nose, and throat medical technology company.
Catalent
Catalent
Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products.
Bristol Myers Squibb
Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products.
Idorsia
Idorsia
Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs.
Amgen
Amgen
Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.
Sanofi
Sanofi
Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
Biogen
Biogen
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
Founding Date
Founding Date
1988
Founding Date
2003
Founding Date
2007
Founding Date
1887
Founding Date
2017
Founding Date
1980
Founding Date
2004
Founding Date
1978
Type
Type
Public
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Tarrytown, US HQ
Mississauga, CA
Courbevoie, FR
München, DE
Bengaluru, IN
Dublin, IE
Limerick, IE
see more
Locations
Menlo Park, US HQ
Locations
Somerset, US HQ
Buenos Aires, AR
Bruxelles, BE
Charleroi, BE
Charleroi, BE
Charleroi, BE
Indaiatuba, BR
see more
Locations
Princeton, US HQ
Mulgrave, AU
Pinewood, AU
Wien, AT
Braine L'alleud, BE
Bruxelles, BE
São Paulo, BR
see more
Locations
Allschwil, CH HQ
Shanghai, CN
Lörrach, DE
Chiyoda City, JP
Locations
Thousand Oaks, US HQ
Hydra, DZ
Vicente López, AR
Sydney, AU
Wien, AT
Diegem, BE
Santo Amaro, BR
see more
Locations
Paris, FR HQ
Hydra, DZ
Macquarie Park, AU
Wien, AT
Dhaka, BD
Brussel, BE
Geel, BE
see more
Locations
Cambridge, US HQ
Vicente López, AR
Macquarie Park, AU
Wien, AT
Machelen, BE
São Paul, BR
Toronto, CA
see more
Employees
Employees
13,9264% increase
Employees
4337% increase
Employees
16,9005% decrease
Employees
34,1001% decrease
Employees
8007% increase
Employees
25,200
Employees
86,088
Employees
7,57013% decrease
Valuation ($)
Valuation ($)
102.2 b
Valuation ($)
N/A
Valuation ($)
10.7 b
Valuation ($)
97.8 b
Valuation ($)
N/A
Valuation ($)
170.4 b
Valuation ($)
141.1 b
Valuation ($)
26.7 b

Financial

Revenue (est.)
Revenue (est.)
$13.1b (FY, 2023)
Revenue (est.)
$106.7m (FY, 2021)
Revenue (est.)
$4.4b (FY, 2024)
Revenue (est.)
$45b (FY, 2023)
Revenue (est.)
CHF152.4m (FY, 2023)
Revenue (est.)
$28.2b (FY, 2023)
Revenue (est.)
€43.1b (FY, 2023)
Revenue (est.)
$9.8b (FY, 2023)
Cost of goods
Cost of goods
N/A
Cost of goods
$30m (FY, 2021)
Cost of goods
$3.4b (FY, 2024)
Cost of goods
$10.7b (FY, 2023)
Cost of goods
CHF7.2m (FY, 2023)
Cost of goods
$8.5b (FY, 2023)
Cost of goods
€12.5b (FY, 2023)
Cost of goods
$2.5b (FY, 2023)
Gross profit
Gross profit
N/A
Gross profit
$76.7m (FY, 2021)
Gross profit
$953m (FY, 2024)
Gross profit
$34.3b (FY, 2023)
Gross profit
CHF146.4m (FY, 2023)
Gross profit
$19.7b (FY, 2023)
Gross profit
€34.5b (FY, 2023)
Gross profit
$7.3b (FY, 2023)
Net income
Net income
$4b (FY, 2023)
Net income
($159.6m) (FY, 2021)
Net income
($1b) (FY, 2024)
Net income
$8b (FY, 2023)
Net income
(CHF297.9m) (FY, 2023)
Net income
$6.7b (FY, 2023)
Net income
€5.6b (FY, 2023)
Net income
$1.2b (FY, 2023)

Operating

Countries
Countries
N/A
Countries
N/A
Countries
80 (FY, 2023)
Countries
N/A
Countries
N/A
Countries
100 (FY, 2020)
Countries
N/A
Countries
N/A
Facilities
Facilities
N/A
Facilities
1 (FY, 2016)
Facilities
N/A
Facilities
N/A
Facilities
N/A
Facilities
180 (FY, 2020)
Facilities
N/A
Facilities
N/A
Patents (EU)
Patents (EU)
17 (FY, 2020)
Patents (EU)
N/A
Patents (EU)
N/A
Patents (EU)
N/A
Patents (EU)
N/A
Patents (EU)
21 (FY, 2020)
Patents (EU)
N/A
Patents (EU)
N/A
Patents (US)
Patents (US)
31 (FY, 2020)
Patents (US)
30 (FY, 2016)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
31 (FY, 2020)
Patents (US)
N/A
Patents (US)
21 (FY, 2021)
Patents Issued
Patents Issued
N/A
Patents Issued
77 (FY, 2016)
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
34 (FY, 2021)
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
20 (FY, 2020)
Phase I Trials Products
N/A
Phase I Trials Products
10 (Q2, 2022)
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
20 (FY, 2021)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
9 (FY, 2021)
Phase I Trials Products (Oncology)
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
5 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
8 (Q2, 2022)
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
15 (FY, 2021)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
12 (FY, 2021)
Phase II Trials Products (Oncology)
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
11 (FY, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
9 (Q2, 2022)
Products
Products
11 (FY, 2022)
Products
2 (FY, 2016)
Products
8 k (FY, 2023)
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Projects in R&D Pipeline
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
12 (FY, 2019)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
91 (FY, 2019)
Projects in R&D Pipeline
N/A
Trademarks
Trademarks
20 (FY, 2022)
Trademarks
29 (FY, 2016)
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A

Funding

Total funding raised
Total funding raised
$ 53.9m
Total funding raised
$ 102.9m
Total funding raised
$ 650m
Total funding raised
$ 15.5m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 310m
Total funding raised
N/A
For sources of this data, please see the company profile

View Company Profiles

Intersect ENT
HQ
Menlo Park, US

Intersect ENT is an ear, nose, and throat medical technology company.

View company
Catalent
HQ
Somerset, US
Employees
16,900↓ 5% decrease

Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products.

View company
Bristol Myers Squibb
HQ
Princeton, US
Employees
34,100↓ 1% decrease

Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products.

View company
Idorsia
HQ
Allschwil, CH
Employees
800↑ 7% increase

Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs.

View company